{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:04:14Z","timestamp":1767110654514,"version":"3.48.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypertensive disorders of pregnancy (HDPs) complicate 8% to 9% of all pregnancies. They are a leading cause of maternal and neonatal morbidity and mortality and contribute to over $2.2 billion of health care expenditures annually. In 2023, the FDA first approved a soluble fms-like tyrosine kinase 1 to placental growth factor ratio system for HDP risk stratification; however, little is known about the implementation of such biomarker testing outside of research contexts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>HDP severity drives clinical management and adverse perinatal outcomes. Placental biomarker testing aims to determine which patients are at risk for developing or progressing to the most severe HDPs. Widespread implementation of biomarker testing may increase access though it may not be cost-efficient or practice-changing for individual institutions. Accordingly, further attention must be paid to restrictive testing situations (e.g., low-resource settings) or even off-label uses (e.g., multiple gestations) that may solidify the role of biomarker testing in routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This review aims to outline clinical and institutional considerations for placental biomarker utilization in the context of their FDA-approved uses and to highlight the potential advantages and disadvantages of various testing strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaf115","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:39:24Z","timestamp":1757417964000},"page":"152-162","source":"Crossref","is-referenced-by-count":0,"title":["Considerations for Implementation of Serum Biomarker Testing for Suspected Hypertensive Disorders of Pregnancy"],"prefix":"10.1093","volume":"72","author":[{"given":"Ashten B","family":"Waks","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, MemorialCare Miller Children\u2019s and Women\u2019s Hospital Long Beach , Long Beach, CA ,","place":["United States"]},{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of California Irvine , Orange, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Frasik","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, MemorialCare Miller Children\u2019s and Women\u2019s Hospital Long Beach , Long Beach, CA ,","place":["United States"]},{"name":"Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of California Irvine , Orange, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan C","family":"Oakes","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, MemorialCare Miller Children\u2019s and Women\u2019s Hospital Long Beach , Long Beach, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2025123010594722400_hvaf115-B1","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222","volume":"135","author":"American College of Obstetricians and Gynecologists","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/10641955.2015.1090581","article-title":"Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia\/eclampsia","volume":"34","author":"Shahul","year":"2015","journal-title":"Hypertens Pregnancy"},{"key":"2025123010594722400_hvaf115-B3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2021.14781","article-title":"Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality","volume":"326","author":"US Preventive Services Task Force","year":"2021","journal-title":"JAMA"},{"key":"2025123010594722400_hvaf115-B5","first-page":"e44","article-title":"Low-dose aspirin use for the prevention of preeclampsia and related morbidity and mortality. ACOG Practice Advisory","volume":"132","author":"American College of Obstetricians and Gynecologists","year":"2022","journal-title":"Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000341264","article-title":"Competing risks model in early screening for preeclampsia by biophysical and biochemical markers","volume":"33","author":"Akolekar","year":"2013","journal-title":"Fetal Diagn Ther"},{"key":"2025123010594722400_hvaf115-B7","doi-asserted-by":"crossref","first-page":"e103780","DOI":"10.1016\/j.ebiom.2021.103780","article-title":"Clinical tools and biomarkers to predict preeclampsia","volume":"75","author":"MacDonald","year":"2022","journal-title":"EBioMedicine"},{"key":"2025123010594722400_hvaf115-B8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejogrb.2018.08.587","article-title":"Assessment of NICE and USPSTF guidelines for identifying women at high risk of pre-eclampsia for tailoring aspirin prophylaxis in pregnancy: an individual participant data meta-analysis","volume":"229","author":"Al-Rubaie","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025123010594722400_hvaf115-B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"2025123010594722400_hvaf115-B10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/HYPERTENSIONAHA.117.10182","article-title":"Meta-analysis and systematic review to assess the role of soluble fms-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study","volume":"71","author":"Agrawal","year":"2018","journal-title":"Hypertension"},{"key":"2025123010594722400_hvaf115-B11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"2025123010594722400_hvaf115-B12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"2025123010594722400_hvaf115-B13","doi-asserted-by":"crossref","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"key":"2025123010594722400_hvaf115-B14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/clinchem\/hvaf024","article-title":"Placental biomarker testing for evaluation of suspected preeclampsia","volume":"71","author":"Silasi","year":"2025","journal-title":"Clin Chem"},{"key":"2025123010594722400_hvaf115-B15","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.3390\/jcm12227022","article-title":"Factors associated with progression to preeclampsia with severe features in pregnancies complicated by mild hypertensive disorders","volume":"12","author":"Barda","year":"2023","journal-title":"J Clin Med"},{"key":"2025123010594722400_hvaf115-B16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1055\/s-0037-1604103","article-title":"Preterm preeclampsia and timing of delivery: a systematic literature review","volume":"39","author":"Guida","year":"2017","journal-title":"Rev Bras Ginecol Obstet"},{"key":"2025123010594722400_hvaf115-B17","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2201295","article-title":"Treatment for mild chronic hypertension during pregnancy","volume":"386","author":"Tita","year":"2022","journal-title":"N Engl J Med"},{"key":"2025123010594722400_hvaf115-B18","doi-asserted-by":"crossref","first-page":"100280","DOI":"10.1016\/j.ajogmf.2020.100280","article-title":"Evaluating the maternal and perinatal seqeuale of severe gestational hypertension","volume":"3","author":"Kumar","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2025123010594722400_hvaf115-B19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1055\/s-0039-1679916","article-title":"Maternal and infant adverse outcomes associated with mild and severe preeclampsia during the first year after delivery in the United States","volume":"37","author":"Ton","year":"2020","journal-title":"Am J Perinatol"},{"key":"2025123010594722400_hvaf115-B20","author":"Fingar"},{"key":"2025123010594722400_hvaf115-B21","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1080\/14767058.2017.1333101","article-title":"Outpatient versus inpatient management for superimposed preeclampsia without severe features: a retrospective, multicenter study","volume":"31","author":"Schoen","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025123010594722400_hvaf115-B22","doi-asserted-by":"crossref","first-page":"101173","DOI":"10.1016\/j.preghy.2024.101173","article-title":"Inpatient versus outpatient management of gestational hypertension or preeclampsia without severe features","volume":"39","author":"Neuburg","year":"2025","journal-title":"Pregnancy Hypertens"},{"key":"2025123010594722400_hvaf115-B23","author":"Thermo Fisher Scientific"},{"key":"2025123010594722400_hvaf115-B24","author":"Roche Diagnostics"},{"key":"2025123010594722400_hvaf115-B25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/jalm\/jfaf063","article-title":"Reference range determination for the sFlt-1:PlGF ratio in a diverse cohort of pregnant women in the United States","volume":"10","author":"Saad","year":"2025","journal-title":"J Appl Lab Med"},{"key":"2025123010594722400_hvaf115-B26","author":"FDA"},{"key":"2025123010594722400_hvaf115-B27","author":"FDA"},{"key":"2025123010594722400_hvaf115-B28","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1097\/AOG.0000000000005576","article-title":"ACOG clinical practice update: biomarker prediction of preeclampsia with severe features","volume":"143","author":"American College of Obstetricians and Gynecologists","year":"2024","journal-title":"Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B29","author":"National Institute for Health and Care Excellence"},{"key":"2025123010594722400_hvaf115-B30","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/01.hjh.0000573064.05528.af","article-title":"Prevalence of gestational hypertension and factors influence selection of antihypertensive drugs in pregnancy","volume":"37","author":"Sadanandan","year":"2019","journal-title":"J Hypertens"},{"key":"2025123010594722400_hvaf115-B31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.bpobgyn.2011.01.006","article-title":"Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy","volume":"25","author":"Hutcheon","year":"2011","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2025123010594722400_hvaf115-B32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/jch.14254","article-title":"Prevalence of hypertensive disorders during pregnancy in France (2010\u20132018): the nationwide CONCEPTION study","volume":"23","author":"Olie","year":"2021","journal-title":"J Clin Hypertens"},{"key":"2025123010594722400_hvaf115-B33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.preghy.2017.10.001","article-title":"Progression of gestational hypertension to preeclampsia: a cohort study of 20,103 pregnancies","volume":"10","author":"Chen","year":"2017","journal-title":"Pregnancy Hypertens"},{"key":"2025123010594722400_hvaf115-B34","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41440-022-01013-z","article-title":"Exponential increase of the gestational-age-specific incidence of preeclampsia onset (COPE study): a multicenter retrospective cohort study in women with maternal check-ups at &lt;20 weeks of gestation in Japan","volume":"45","author":"Ohkuchi","year":"2022","journal-title":"Hypertens Res"},{"key":"2025123010594722400_hvaf115-B35","doi-asserted-by":"crossref","first-page":"e232110","DOI":"10.1001\/jamahealthforum.2023.2110","article-title":"Obstetric volume and severe maternal morbidity among long-risk patients giving birth at rural and urban US hospitals","volume":"4","author":"Kozhimannil","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2025123010594722400_hvaf115-B36","doi-asserted-by":"crossref","first-page":"e0156013","DOI":"10.1371\/journal.pone.0156013","article-title":"Influence of the sFlt-1\/PlGF ratio on clinical decision-making in women with suspected preeclampsia","volume":"11","author":"Klein","year":"2016","journal-title":"PLoS One"},{"key":"2025123010594722400_hvaf115-B37","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.3390\/ijerph20075418","article-title":"Psychological impact and women\u2019s evaluation of the first trimester preeclampsia screening and prevention trial: ASPRE trial","volume":"20","author":"Nikcevic","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"2025123010594722400_hvaf115-B38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pd.1970120309","article-title":"The psychological effects of false-positive results in prenatal screening for fetal abnormalities: a prospective study","volume":"12","author":"Marteau","year":"1992","journal-title":"Prenat Diagn"},{"key":"2025123010594722400_hvaf115-B39","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.midw.2014.04.006","article-title":"The psychological impact of providing women with risk information for preeclampsia: a qualitative study","volume":"30","author":"Harris","year":"2014","journal-title":"Midwifery"},{"key":"2025123010594722400_hvaf115-B40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pd.4485","article-title":"Psychological impact of first-trimester prevention for preeclampsia on anxiety","volume":"35","author":"Simeone","year":"2015","journal-title":"Prenat Diagn"},{"key":"2025123010594722400_hvaf115-B41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/00016340903008953","article-title":"Are tests for predicting preeclampsia good enough to make screening viable? A review of reviews and critical appraisal","volume":"88","author":"Cnossen","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2025123010594722400_hvaf115-B42","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/AOG.0000000000003020","article-title":"Chronic hypertension in pregnancy. ACOG Practice Bulletin No. 203","volume":"133","author":"American College of Obstetricians and Gynecologists","year":"2019","journal-title":"Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B43","doi-asserted-by":"crossref","first-page":"e2301","DOI":"10.1136\/bmj.g2301","article-title":"Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis","volume":"348","author":"Bramham","year":"2014","journal-title":"BMJ"},{"key":"2025123010594722400_hvaf115-B44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1471-0528.2004.00516.x","article-title":"The natural history of white coat hypertension during pregnancy","volume":"112","author":"Brown","year":"2005","journal-title":"BJOG"},{"key":"2025123010594722400_hvaf115-B45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/hc3701.096100","article-title":"Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] study)","volume":"104","author":"Sega","year":"2001","journal-title":"Circulation"},{"key":"2025123010594722400_hvaf115-B46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11906-024-01309-0","article-title":"White coat hypertension & cardiovascular outcomes","volume":"26","author":"Townsend","year":"2024","journal-title":"Curr Hypertens Rep"},{"key":"2025123010594722400_hvaf115-B47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/HYPERTENSIONAHA.119.14627","article-title":"Maternal and perinatal outcomes of white coat hypertension during pregnancy","volume":"76","author":"Johnson","year":"2020","journal-title":"J Hypertens"},{"key":"2025123010594722400_hvaf115-B48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41440-023-01509-2","article-title":"sFlt-1\/PIGF ratio positive associated with non-dipper type change in ambulatory blood pressure monitoring (ABPM) for preeclampsia development","volume":"47","author":"Chen","year":"2024","journal-title":"Hypertens Res"},{"key":"2025123010594722400_hvaf115-B49","doi-asserted-by":"crossref","first-page":"100359","DOI":"10.1016\/j.xagr.2024.100359","article-title":"Sflt1\/PlGF among patients with suspected preeclampsia when considering hypertensive status","volume":"4","author":"Patel","year":"2024","journal-title":"AJOG Glob Rep"},{"key":"2025123010594722400_hvaf115-B50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.preghy.2020.11.010","article-title":"Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource setting: ROBUST study","volume":"23","author":"Soundararajan","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"2025123010594722400_hvaf115-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2022.09.003","article-title":"Economic impact analysis of incorporation of Elecys sFlt-1:PlGF ratio into routine practice for the diagnosis and follow-up of pregnant women with suspected preeclampsia in Argentina","volume":"34","author":"Garay","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"2025123010594722400_hvaf115-B52","doi-asserted-by":"crossref","first-page":"385.e1","DOI":"10.1016\/j.ajog.2024.07.015","article-title":"Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1\/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy","volume":"232","author":"Burns","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B53","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1080\/14767058.2016.1183631","article-title":"First trimester uterine artery Doppler, sFlt-1 and PlGF to predict preeclampsia in a high-risk population","volume":"30","author":"Diguisto","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025123010594722400_hvaf115-B54","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/uog.17373","article-title":"sFlt-1\/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain)","volume":"50","author":"Perales","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025123010594722400_hvaf115-B55","doi-asserted-by":"crossref","first-page":"2230514","DOI":"10.1080\/14767058.2023.2230514","article-title":"sFlt-1\/PlGF ratio as a predictor of pregnancy outcomes in twin pregnancies: a systematic review","volume":"36","author":"Satorres","year":"2023","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025123010594722400_hvaf115-B56","author":"Centers for Disease Control and Prevention (U.S.)Office of Surveillance, Epidemiology, and Laboratory ServicesDivision of Laboratory Science and StandardsLaboratory Science, Policy, and Practice Program Office"},{"key":"2025123010594722400_hvaf115-B57","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/s41467-025-58157-y","article-title":"Molecular subtyping of hypertensive disorders of pregnancy","volume":"16","author":"Elovitz","year":"2025","journal-title":"Nat Commun"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/1\/152\/66163269\/hvaf115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/1\/152\/66163269\/hvaf115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:00:02Z","timestamp":1767110402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/72\/1\/152\/8407346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2025,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaf115","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,30]]}}}